Prevention of Damage Induced by Facial Mask Ventilation

NCT ID: NCT01351155

Last Updated: 2014-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

252 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In patients with acute respiratory failure (ARF) undergoing noninvasive ventilation (NIV), the main complication of the use of the mask is the development of decubitus, sometimes so severe and painful as to force a suspension of the NIV itself . The lesions are mainly located at the nasal bridge, as at this level the skin thin and placed directly on the bone is particularly vulnerable to the injury as consequence of the friction and pressure induced by the movement of the mask. The strategy of prevention and treatment commonly adopted is the application of hydrocolloids.

However, precise data are lacking about the demonstration of the effectiveness of these devices and the possibility of using other protective devices.

The purpose of this study was to evaluate the usefulness of large-scale three different systems of protection vs. no protection in preventing the development of decubitus lesions in patients receiving NIV for an episode of ARF.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NIV is a form of ventilatory support which is popular overall in the world. The patient interface most commonly used in the course of NIV is by far the nasal or oronasal mask. The main complication of the use of the mask is the development of decubitus, sometimes so severe and painful as to force a suspension of NIV. The decubitus is mainly located at the nasal bridge, as at this level the skin thin and placed directly on the bone. According to Meduri et al.(Chest 1996) the duration of NIV, age, type of respiratory failure, the pressure used for ventilation and the level of albumin did not influence the development of necrosis.

Severe skin injury with ulceration and necrosis occurs in approximately 10% of patients receiving NIV trained in services. In the multicenter evaluation of a new face mask dedicated to the NIV (Gregoretti et al, Intens Care Med 2002) describes the development of NIV-induced decubitus in 100% of the control group treated with masks "traditional", with an average grade of 2.79 on a scale of Assessment Standard ranging from 1 (erythema) to 4 (necrosis).

The strategy of prevention and treatment commonly adopted is the application of appropriately shaped hydrocolloids. However, the data relating to the use of protective systems for the prevention of NIV-induced decubitus are limited and controversial. In a first pilot study (Callaghan et al,Professional Nurse 1998, the authors compared the protective efficacy of two types of "dressing" (Granuflex, Spenco Dermal and 10 patients, 10 patients) vs a non-randomized control group (10 patients): 30 patients in total . In this work, which presents a problem of inter-observer variability, the "Granuflex group" (or Duoderm) showed a greater protective effect (3 vs. 7 lesions in "Spenco Dermal group" vs 9 lesions in the control group). Recently, in a larger study, Weng (Intensive Crit Care Nurs 2008) compared the efficacy of two devices (Tegaderm and tegasorb) vs. a control group in 90 patients (30 per group) undergoing NIV. The rate of lesions was significantly lower in the treated groups (53% Tegaderm; Tegasorb 40%) than in the control group (96.7%), with no significant difference between the two interventional arms on both the incidence and the timing of onset of injury.

Therefore, given the limited data currently available regarding both the effectiveness and the choice of a protective device and in consideration of the continuous expansion of NIV in the acute setting, in our opinion it's seems to us justified to perform a controlled study comparing different types of devices in terms of skin protection during NIV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

acute respiratory failure noninvasive ventilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

polyurethane foam (Allewyn adesive)

Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown

Group Type ACTIVE_COMPARATOR

Skin protective dressing device

Intervention Type DEVICE

Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury

polyurethane film (Tegaderm)

The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown

Group Type ACTIVE_COMPARATOR

Skin protective dressing device

Intervention Type DEVICE

Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury

Hydrocolloid (Duoderm)

Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown

Group Type ACTIVE_COMPARATOR

Skin protective dressing device

Intervention Type DEVICE

Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury

Control

In this no-intervention arm, any skin protective dressing devices is applied before NIV starting

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skin protective dressing device

Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypoxemic-hypercapnic acute respiratory failure (while in O2-therapy):

1. pH\<7.30,
2. PaCO2\>50 mmHg,
3. PaO2/FiO2\<250,
4. respiratory rate\>25/min and use of accessory respiratory muscles
* Pure Hypoxemic acute respiratory failure(while in O2-therapy):

1. pH\>7.35
2. PaCO2\< 50 mmHg
3. PaO2/FiO2\<250
4. respiratory rate\>25/min and use of accessory respiratory muscles

For both types of acute respiratory failure: Signed informed consent by the patient or next keen. Age more than 20 year's old

Exclusion Criteria

1. cardiac arrest
2. severe hemodynamic instability (\> 1 vasoactive amine for more than 24 hours)
3. acute coronary syndrome (instable angina/AMI)
4. refusal of NIV
5. anatomic abnormalities interfering with mask fitting
6. pre-existent nasal lesions;
7. NIV for\< 24 hours
8. kwon hypersensitivity to hydrocolloid and polyurethane
9. cancel of informed consent
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role collaborator

Italian Association of Hospital Pneumologists

OTHER

Sponsor Role collaborator

Ospedale San Donato

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raffaele Scala

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raffaele Scala, MD, FCCP

Role: STUDY_CHAIR

PULMONARY DIVISION WITH RESPIRATORY INTENSIVE CARE UNIT, S. DONATO HOSPITAL, AREZZO, ITALY

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pulmonary Division With Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy

Lucca, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Raffaele Scala, MD, FCCP

Role: CONTACT

Phone: +39 3482605980

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Weng MH. The effect of protective treatment in reducing pressure ulcers for non-invasive ventilation patients. Intensive Crit Care Nurs. 2008 Oct;24(5):295-9. doi: 10.1016/j.iccn.2007.11.005. Epub 2008 Feb 1.

Reference Type RESULT
PMID: 18242994 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RSAIPO2011

Identifier Type: -

Identifier Source: org_study_id